Aligos Therapeutics Prices IPO Of 10 Mln Shares At $15/Shr, Mid Of Expected Range

By RTTNews Staff Writer   ✉   | Published:

Aligos Therapeutics, Inc. (ALGS) announced the pricing of initial public offering of 10 million common shares at $15.00 per share, the mid of the expected range of between $14.00 and $16.00 per share. The offering is expected to close on October 20, 2020.

In addition, Aligos has granted the underwriters a 30-day option to buy additional 1.5 million common shares at the initial public offering price.

The company expects offering gross proceeds, before expenses, to be about $150.0 million, excluding any exercise of the underwriters' option to purchase additional shares.

Aligos' common stock is expected to begin trading on the Nasdaq Global Select Market on October 16, 2020, under the ticker symbol "ALGS".

J.P. Morgan, Jefferies and Piper Sandler are acting as the joint book-running managers for the offering. Cantor is acting as a lead manager for the offering.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Hadson Toko Trading Co., Inc. is recalling Eishindo jelly cups citing a potential choking hazard, the U.S. Food and Drug Administration announced. The recall involves 28.2 ounces or 800g bags of Eishindo Mini Cup Jelly (50pcs). The recalled jelly cups were distributed across the nation in retail food stores and are sold in large clear bags of 50 jelly cups. Electric car maker Tesla Inc. has cut the price of its Model S Long Range sedan. Chief Executive Elon Musk tweeted, "The gauntlet has been thrown down! The prophecy will be fulfilled. Model S price changes to $69,420 tonight!" Further, in a reply to a tweet, Musk confirmed that Tesla is starting production on Model Y seven seater next month, with plans for initial deliveries in early December. Financial services firm Morgan Stanley reported Thursday a profit for the third quarter that increased 26 percent from last year, reflecting 16 percent revenue growth amidst strength across all business segments. Both adjusted earnings per share and quarterly net revenues topped analysts' expectations.